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Abstract: Aflatoxins are toxic compounds produced by molds of the Aspergillus species that con-
taminate food primarily in tropical countries. The most toxic aflatoxin, aflatoxin B1 (AFB1), is a
major cause of hepatocellular carcinoma (HCC) in these countries. In sub-Saharan Africa, aflatoxin
contamination is common, and perinatal AFB1 exposure has been linked to the early onset of HCC.
Epigenetic programming, including changes to DNA methylation, is one mechanism by which
early life exposures can lead to adult disease. This study aims to elucidate whether perinatal AFB1
exposure alters markers of offspring health including weight, lipid, and hormone profiles as well as
epigenetic regulation that may later influence cancer risk. Pregnant rats were exposed to two doses
of AFB1 (low 0.5 and high 5 mg/kg) before conception, throughout pregnancy, and while weaning
and compared to an unexposed group. Offspring from each group were followed to 3 weeks or
3 months of age, and their blood and liver samples were collected. Body weights and lipids were
assessed at 3 weeks and 3 months while reproductive, gonadotropic, and thyroid hormones were
assessed at 3 months. Prenatal AFB1 (high dose) exposure resulted in significant 16.3%, 31.6%, and
7.5% decreases in weight of the offspring at birth, 3 weeks, and 3 months, respectively. Both doses of
exposure altered lipid and hormone profiles. Pyrosequencing was used to quantify percent DNA
methylation at tumor suppressor gene Tp53 and growth-regulator H19 in DNA from liver and blood.
Results were compared between the control and AFB1 exposure groups in 3-week liver samples and
3-week and 3-month blood samples. Relative to controls, Tp53 DNA methylation in both low- and
high-dose exposed rats was significantly decreased in liver samples and increased in the blood (p <
0.05 in linear mixed models). H19 methylation was higher in the liver from low- and high-exposed
rats and decreased in 3-month blood samples from the high exposure group (p < 0.05). Further
research is warranted to determine whether such hormone, lipid, and epigenetic alterations from
AFB1 exposure early in life play a role in the development of early-onset HCC.
Keywords: aflatoxin B1; liver; lipid; hormones; DNA methylation; developmental origins of health
and disease; gestational exposure
1. Introduction
The developmental origins of health and disease (DOHaD) paradigm posits that
environmental conditions in gestation and early postnatal life set the stage for the health
trajectory of offspring throughout their lifetime [1]. Early evidence for DOHaD included
studies showing that adults were at a much higher risk for coronary heart disease or
ischemic heart disease if they were small at birth and remained small in the first two
years of life [1,2]; rapid weight gain and catch-up growth later in childhood seemed to
underlie some of this risk [2]. Decades of research in this field to date have shown that
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environmental factors ranging from macro-and micronutrient availability to chemical and
biological agent exposures early in life can lead to fetal and perinatal adaptive responses
that impact development, growth, metabolism, and ultimately ‘program’ the offspring for
adult disease. In addition to coronary and other metabolic diseases, evidence now shows
that the early life environment can also increase the risk for the development of cancer,
especially hormone-dependent cancers [3]. Birthweight is often a proxy for the impact of
the gestational environment and a predictor for health in years to come; a recent systematic
review suggests that high birth weight is associated with overall and prostate cancer
mortality [4]. Low birth weight has been shown to be associated with hepatoblastoma [5,6],
liver diseases, and HCC in adulthood [7,8].
One of the many biological mechanisms that are at play in the DOHaD is epigenetic
alteration. Here we define epigenetic modifications as mitotically and in some cases,
meiotically heritable modifications to DNA and chromatin that control the expression of
genes without altering the DNA sequence [9,10]. Aberrant epigenetic gene regulation
has been proposed as a mechanism of action for non-genotoxic carcinogenesis [11] and is
also important for fetal and childhood growth and development, including the imprinted
genes Igf2 and H19 and non-imprinted gene Igf1 [12–14]. The epigenome is vulnerable to
deregulation during embryogenesis due to the waves of epigenetic erasure (i.e., demethy-
lation post-fertilization) and post-implantation reprogramming that occur [10]. Disruption
during this reprogramming stage can be passed on to all subsequent cells across tissue
types. DNA methylation is one mechanism of epigenetic regulation that is stable across
time at many cytosine-guanine (CpG) dinucleotides [15]. Environmental exposures, espe-
cially during early gestation, may perturb epigenetic programming and set the stage for
disease development later in life; exposures to chemicals such as bisphenols and phthalates
have been shown to alter the offspring epigenome [16–18]. Recent studies have implicated
naturally-occurring mycotoxins, including aflatoxin B1 (AFB1) as epigenetic-modifying
exposures [19–23].
Aflatoxins are secondary metabolite products of Aspergillus species molds, and human
exposure to these toxins occurs due to exposure to contaminated food such as grains, nuts,
eggs, spices, milk, and meat in tropical countries of sub-Saharan Africa and southeast
Asia [24,25]. Although aflatoxin contamination is common and a major problem in these
countries, studies have shown that aflatoxin contamination is a global occurrence including
in parts of Europe and the Americas [26–28]. AFB1 is the most toxic and common of all types
of aflatoxins in human populations. AFB1-exo-8,9-epoxide, the highly reactive metabolite
of AFB1 which binds to DNA and forms adducts, has been linked to hepatotoxicity and
carcinogenesis [29–31]. Liver cancer is the fourth most frequent cancer in sub-Saharan
Africa [32], and the increase of liver cancer in this region has been associated with exposures to
both hepatitis B virus and AFB1 [33]. In addition to DNA adduct formation, there is evidence
for an epigenetic change in the liver following exposure to AFB1 among adults [20,21].
African children are known to be exposed to AFB1 during gestation, breastfeeding, and
through grain-based weaning foods [34]. While early-life exposure has been linked to growth
faltering [34] and changes to DNA methylation in one epidemiological study [19], this is
still a new area of research that has not been studied in animal or human models of chronic
exposure with long-term follow-up past birth.
The early onset of carcinogenesis involves epigenetic changes in tumor suppressor
genes [20,35]. Tp53 encodes p53, a tumor suppressor known for its role in cancer preven-
tion [36,37]. Apart from this role, studies now show that it plays additional functions,
including regulation of liver metabolism and homeostasis [38]. P53 is also involved in
lipid and hormone metabolic pathways [38–40]. There is evidence suggesting interactions
between p53 and hormones could be involved in carcinogenesis [38,40–42]. Previous
studies from our lab and others have shown that AFB1 dysregulates the metabolism of
lipids [43–45] and hormones [46–48] in rats. Growing evidence implicates imprinted genes,
including Igf2 and H19, which are typically known for their roles in early-life growth, to
contribute to risk for cancers [49–51].
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In this study, we seek to understand the effect of two doses of AFB1 exposure using a
perinatal rat exposure model (gestation through weaning) on epigenetic programming in
the offspring and other physiological indicators of health and disease risk (hormone levels,
lipid levels, and weight). Specifically, we assess DNA methylation at Tp53, a crucial tumor
suppressor gene, and H19, an environmentally-responsive imprinted gene that has been
linked to HCC risk. DNA methylation at these genes was quantified immediately following
cessation of exposure (3 weeks of age) and in early adulthood (3 months of age) in the liver,
the target tissue of interest, as well as blood, the surrogate tissue most often accessible in
human studies. We also measured weight, cholesterol, triglycerides, and hormones. We
hypothesized that perinatal exposure to AFB1 would reduce offspring growth, decrease
hormone and lipid levels, and alter DNA methylation. We also hypothesized that these
changes would be detected in both liver and blood and persist until adulthood after
exposure ceases.
2. Materials and Methods
2.1. Animals
Ethical approval for the use of animals in this research was given by Covenant Uni-
versity Health Research Ethics Committee (protocol number CHREC/026/2018), and all
procedures were in strict compliance with set ethical standards. Eighteen 6-week-old inbred
female and nine male Wistar rats weighing between 100 and 120g were purchased from
Lagos University Teaching Hospital (LUTH), Lagos, Nigeria, and used for this experiment.
Animals were housed in clean, well-ventilated cages for standard 12-h light and dark cycles
at room temperature in the animal house in Covenant University, Nigeria. Animals were
fed standard rat chow and clean water ad libitum and allowed to acclimatize for 3 weeks
prior to the start of the experiment.
2.2. Chemicals
AFB1 was obtained from Sigma-Aldrich (St. Louis, MI, USA) while kits for hormone
and lipid profiles were products of Biobase (Jinan, China) and Randox (Crumlin, UK)
respectively.
2.3. Experimental Design
Female animals were randomly distributed into 3 groups of 6 animals each and
administered feed containing one of two doses (0.5 or 5.0 mg/kg feed) of AFB1 while the
third group served as control. The doses were chosen based on the concentrations of AFB1
found in maize grains in Nigeria [52]. Mating was achieved by placing one male animal
in a cage with two females and ended once a vaginal plug was detected. AFB1 treatment
began two weeks prior to mating and lasted throughout pregnancy, ending precisely
three weeks after the birth of the offspring. This is a perinatal exposure model that has been
employed in other environmental epigenetic research studies [16]. To ensure that animals
maintained a healthy weight, body weights were measured biweekly throughout the
experiment, up until the time of euthanasia. At weaning (3 weeks), half of the litters were
weighed and anesthetized using 50 mg ketamine/5 mg xylazine followed by euthanasia
using a protocol approved by the Covenant University Ethics Committee (protocol number
CHREC/026/2018). Blood was collected via cardiac puncture using syringes coated with
lithium heparin. Whole blood was centrifuged at 3000 rpm for 15 minutes to obtain plasma
which was used for hormonal assays and lipid profile analysis. The whole liver was excised,
rinsed in phosphate buffer saline, and frozen for further analysis. The remaining offspring
were fed a diet free of AFB1 up to 3 months of age, at which point they were also euthanized
for blood and liver collection.
2.4. Hormone and Lipid Analysis
The hormone profile (testosterone, progesterone, estradiol, follicle-stimulating hor-
mone (FSH), luteinizing hormone (LH), prolactin, thyroxine (T4), and triiodothyronine
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(T3)) was assessed in the plasma using ELISA kits purchased from Biobase (Jinan, China),
and following the manufacturer’s instructions. Briefly, samples or standards were added
to microplate wells previously coated with specific antibody after which horseradish per-
oxidase conjugate was added and incubated at 37 ◦C for one hour. After incubation, wells
were washed five times and chromogen was added for color formation. Absorbance was
measured spectrophotometrically at 450 nm using a plate reader. Total plasma cholesterol
and triglycerides were measured using commercially available kits (Randox).
2.5. DNA Methylation Analysis
High-molecular-weight DNA was extracted from 3-week and 3-month liver and blood
samples using DNA DNeasy® Blood and Tissue extraction (Qiagen, Germantown, MD,
USA) kits according to the protocol of the manufacturer. DNA samples were shipped
on dry ice to the University of Michigan and stored at −80 ◦C until analysis. DNA
samples were then treated with sodium bisulfite using kits from Zymo Research (Irvine,
CA, USA) [53]. DNA methylation was quantitatively analyzed at cytosine-phosphate-
guanine dinucleotides (CpG sites) via pyrosequencing [54] at Tp53 (9 CpG sites) and H19
(6 sites). Primer designs were modified using PyroMark Assay Design Software 2.0 (Qiagen,
Germantown, MD, USA) to amplify regions in the promoters of Tp53 and H19 based on
assays previously used by others (see primer sequences in Supplemental Table S1) [13,55].
The H19 assay covers the second imprinting control region (ICR2) of the gene. For all genes,
sequences were amplified with HotStarTaq Master Mix (Qiagen) from approximately 50 ng
bisulfite-converted DNA. At least four replicates of commercial rat DNA and negative
controls were included in each batch (96-well PCR/pyrosequencing plate). The percentage
of methylated cells was quantified by a PyroMark ID Pyrosequencer (Qiagen). Pyro
Q-CpG Software computes percent methylation and performs internal quality control
checks to ensure complete bisulfite conversion, adequate signal over background noise, etc.
Only samples and CpG sites passing quality control were used for downstream statistical
analyses. A subset of samples (>10%) were run in duplicate, and duplicate reads were
averaged when available.
2.6. Statistical Analysis
Descriptive statistics were calculated first for all continuous variables (weights, site-
specific DNA methylation), and frequencies for categorical variables. Two-sided t-tests
assuming unequal variances were conducted to compare birth weight and weight at
sacrifice between all offspring and sex-stratified offspring for the following comparisons:
control vs. low exposure group, control vs. high, and low vs. high. Mixed-effects
regression was also performed on weight as a repeated measure (stages: at birth, 3 weeks,
and 3 months), adjusting for sex. An interaction term between stage and exposure group
was tested as well as a random intercept for a dam. The latter did not improve the model
fit and was excluded in the final model. Hormone and lipid data were analyzed using
SPSS v23 (IBM Corp., Armonk, NY, USA). One-way analysis of variance (ANOVA) with
post-hoc tests was used to compare the means in each exposure group.
Before analysis of DNA methylation data, CpG sites and/or samples that failed quality
control checks were removed. DNA quality from one set of samples (3-month liver) was
low, and most of these samples failed quality control. Thus, 3-month livers were excluded
from statistical analyses. For Tp53, DNA methylation data had a higher passing rate for
the first 6 CpG sites in the assay. As such, only samples that passed for all 6 CpG sites
were included in further analyses. These 6 CpG sites were highly correlated with one
another (Spearman rho > 0.5 for intra-site comparisons with most >0.75), and we averaged
them together. The six CpG sites of H19 were highly correlated (Spearman rho > 0.7), and
we averaged the sites together for most statistical analyses. We first compared average
values for each gene across all exposure groups within 3-week livers, 3-week blood, and
3-month blood samples separately using ANOVA. We utilized Welch’s F-test instead if
variances between groups were not homogenous according to Levene’s test. To better
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capture intra-gene variability at each CpG site, we performed mixed-effects regression, [56]
where the outcome is a repeated measure of DNA methylation at multiple CpG sites. Based
on the correlation structure between the sites, we assumed an autoregressive covariance
structure between Tp53 sites (all 9 CpG sites included) and compound symmetry for H19
(all 6 CpG sites). Models were run separately for liver (adjusting for CpG site and sex) and
blood (adjusting for CpG site, sample time point, and sex) data with exposure group as
the predictor of interest. We also included a random intercept for litter in H19 methylation
models as litter explained a portion of the covariance for H19 but not for Tp53.
Unless otherwise specified, statistical analyses were conducted in SAS version 9.4 (SAS
Institute Inc., Cary, NC, USA), and p-values < 0.05 were considered statistically significant.
3. Results
3.1. Weight Gain/Weight Status of the Rodent Population
Offspring from the unexposed control group (41 from 6 dams), the low dose exposure
group (48 from 5 dams), and the high dose exposure group (36 from 4 dams) were followed
up to either 3 weeks of age or 3 months of age. Weights were measured at birth and at the
time of sacrifice. At birth, offspring of the high exposure group were significantly lower
in weight by 0.8g and 1.3g for females and males, respectively (Table 1) compared to the
control group. At 3 weeks of age, offspring from both the low and high exposure groups
were statistically significantly lower in weight than the control group when comparing
all offspring or males and females separately. At 3 months of age, the control group still
had the highest weights. Statistically significant differences were noted when comparing
the low group to the control group or the low to the high group. When modeling all
weight data from 125 offspring as a repeated measure, adjusting for sex and stage, the
exposure group was still statistically significant (p < 0.0001 for fixed effect of exposure and
for interaction between exposure-group and timing).
Table 1. Prenatal Aflatoxin B1 Exposure and Offspring Weight (g).
Exposure
Group Offspring
At Birth 3 Weeks 3 Months
Mean (SD) N Mean (SD) N Mean (SD) N
Control All 6.3 (1.5) 41 47.9 (5.1) 19 191 (28.8) 22
Females 6.2 (1.5) 22 46.1 (3.6) 11 167 (13.7) 11
Males 6.5 (1.6) 19 50.0 (6.0) 8 217 (12.7) 11
0.5 mg/kg All 6.3 (1.1) 48 34.6 (6.7) ** 19 155 (12.8) ** 29
Females 6.4 (1.2) 20 34.9 (7.4) * 9 158 (11.9) 11
Males 6.3 (1.0) 28 34.3 (6.5) ** 10 153 (13.4) ** 18
5.0 mg/kg All 5.3 (0.7) ** ## 36 32.7 (4.2) ** 17 177 (33.6) # 19
Females 5.4 (0.8) * # 21 33.8 (4.5) ** 10 153 (15.8) * 11
Males 5.2 (0.7) * ## 15 31.1 (3.4) ** 7 209 (23.2) ## 8
* p < 0.05 and ** p < 0.001 when compared to control within same time period and offspring group (all, females or
males). # p < 0.05 and ## p < 0.001 when compared to low group within same time period and offspring group (all,
females, or males).
3.2. Lipids
Total cholesterol and triglycerides were measured in plasma samples from 3 weeks
and 3 months animals. Within each exposure group, cholesterol and triglycerides decreased
as the animals aged (Table 2). At the time exposure ceased (3 weeks), cholesterol levels
were 32% and 36% lower in the low and high exposure groups, respectively, compared
to controls (p < 0.05). At 3 months of age, differences remained though, at that time,
both exposure groups had 19% lower cholesterol compared with controls (p < 0.05). At
3 weeks, triglycerides were significantly higher in low and high exposure groups (14% and
18%, respectively, p < 0.05). At 3 months of age, the low exposure group was no longer
significantly different from the control group, yet the high exposure group retained a 19%
higher level of triglycerides compared to controls. However, when we stratified by sex, the
Int. J. Environ. Res. Public Health 2021, 18, 589 6 of 15
higher exposure group had significantly higher triglycerides in both males and females
while the low exposure group of male rats had a significantly lower triglyceride level
compared with control at both time points (stratified results not shown).




Cholesterol (mg/dL) Triglycerides (mg/dL)
3 Weeks 3 Months 3 Weeks 3 Months
Control (no AFB1) 299.16 ± 19.73 a 184.60 ± 11.98 a# 373.44 ± 36.72 a 212.55 ± 12.39 a#
0.5 mg/kg 204.91 ± 17.45 b 148.85 ± 9.83 b# 425.93 ± 25.44 b 200.75 ± 12.50 a#
5.0 mg/kg 190.61 ± 9.98 b 150.22 ± 9.46 b# 439.94 ± 23.52 b 253.52 ± 13.85 a#
Values are Mean ± SD. Values within the same column with different superscripts (a, b) are significantly different
at p < 0.05. # indicates significantly different from 3 weeks within the same exposure group at p < 0.05.
3.3. Hormonal Changes at 3 Months of Age
We observed statistically significant differences between exposure groups when com-
paring reproductive, gonadotropic, and thyroid hormone (Figure 1) levels in 3-month
plasma samples, stratified by sex. Among males, testosterone was lower in the low (p < 0.1)
and high (p < 0.05) exposure groups compared with the control group. Estradiol was higher
and prolactin lower in low exposure males compared to both control and high exposure
groups (p < 0.05). Among females, LH was lower in both exposure groups compared to
controls (p < 0.05). Progesterone was lower in high exposure females only (p < 0.05) and
prolactin was decreased in low exposure group males and females compared to controls.
When assessing thyroid hormones, T4 was decreased in the high exposure group females
compared to controls and the low dose group (p < 0.05). T3 was decreased in males in the
low exposure group (p < 0.01).
3.4. DNA Methylation in Liver and Blood
We observed exposure-dependent differences in Tp53 and H19 DNA methylation in
the liver at 3-weeks of age (Table 3) and in blood at 3-weeks and 3-months (Table 4). In
the liver, the target tissue of interest, Tp53 methylation was lower in both exposure groups
compared to the unexposed group (ANOVA p-value = 0.06). In repeated measures linear
regression of 9 CpG sites of Tp53, taking into account their covariance and adjusting for
sex and CpG site, Tp53 methylation was statistically significantly lower in both exposure
groups compared to unexposed (estimate of −1.09 ± 0.34%, p = 0.002 for low and −0.91 ±
0.34%, p = 0.01 for high). H19 methylation was higher in low and high exposure groups’
liver samples compared to controls (ANOVA p = 0.0041). In repeated measures linear
regression of 6 CpG sites adjusting for sex, site, and dam, these differences remained
statistically significant for the low (effect estimate 5.37 ± 2.56%, p = 0.04) and high (6.88 ±
2.64%, p = 0.0098) exposure groups.
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Figure 1. Early Life AFB1 Exposure and Hormones in 3-month Offspring. Distributions of plasma hormones at 3 months 
of age are shown for male and female offspring of the unexposed (control) and low- and high-exposure groups for the 
following hormones: (a) Testosterone, (b) Progesterone, (c) Estradiol, (d) Prolactin, (e) Luteinizing hormone (LH), (f) Fol-
licle-stimulating hormone (FSH), (g) Triiodothyronine (T3), and (h) Thyroxine (T4). Boxes represent the interquartile range 
(IQR) while the line inside each box represents the median. The whiskers represent 1.5 × IQR while the dots are outliers. * 
Denotes significantly different from control at p < 0.05, # significantly different from control at p < 0.01, ^significantly dif-
ferent from the low exposure group at p < 0.05. 
Figure 1. Early Life AFB1 Exposure and Hormones in 3-month Offspring. Distributions of plasma hormones at 3 months
of age are shown for male and female offspring of the unexposed (control) and low- and high-exposure groups for the
following hormones: (a) Testosterone, (b) Progesterone, (c) Estradiol, (d) Prolactin, (e) Luteinizing hormone (LH), (f) Follicle-
stimulating hormone (FSH), (g) Triiodothyronine (T3), and (h) Thyroxine (T4). Boxes represent the interquartile range
(IQR) while the line inside each box represents the median. The whiskers represent 1.5 × IQR while the dots are outliers.
* D otes significantly different from control at p < 0.05, # significantly different from control at p < 0.01, ˆ significantly
different from the low exposure group at p < 0.05.
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Table 3. DNA Methylation by Aflatoxin B1 Exposure Group at 3 Weeks of Age in Liver.
Tp53 H19
Exposure Group Mean (SD) N ANOVAp-Value
Effect
Estimate (SE) p-Value Mean (SD) N
ANOVA
p-Value Effect Estimate (SE) p-Value
Control 5.99 (1.46) 16 0.06 ref 49.56 (9.54) 18 0.0041 ref
Low—0.5 mg/kg 4.82 (1.54) 16 −1.09 (0.34) 0.002 55.33 (4.60) 18 5.37 (2.56) 0.04
High—5.0 mg/kg 5.12 (1.19) 16 −0.91 (0.34) 0.01 56.80 (3.51) 17 6.88 (2.64) 0.0098
For each exposure group, Mean ± SD of percent methylation at each gene is shown along with a p-value from ANOVA comparing the groups. Mixed-effects regression was also performed, and effect estimates
are shown for the exposure group. For Tp53, the outcome consists of repeat measures of DNA methylation at 9 CpG sites, and the model adjusts for offspring sex and CpG site. For H19, the outcome is repeat
measures at 6 CpG sites, and the model adjusts for sex, site, and a random intercept for dam.
Table 4. DNA Methylation by Aflatoxin B1 Exposure Group at 3 Weeks and 3 Months of Age in Blood.
Tp53 H19
Exposure Group Mean (SD) N ANOVAp-Value
Effect
Estimate (SE) p-Value Mean (SD) N
ANOVA
p-Value Effect Estimate (SE) p-Value
3-weeks
Control 3.10 (2.44) 18 0.07 * ref 41.74 (2.68) 18 0.08 ref
Low—0.5 mg/kg 4.55 (2.61) 18 1.69 (0.73) 0.02 40.79 (2.16) 18 −0.80 (1.04) 0.44
High—5.0 mg/kg 6.15 (4.86) 14 3.42 (0.78) <0.0001 42.83 (2.88) 16 1.07 (1.08) 0.32
3-months
Control 0.82 (1.20) 20 <0.001 ref 52.87 (16.08) 17 0.038 ref
Low—0.5 mg/kg 2.48 (1.94) 23 1.52 (0.38) 0.0002 42.96 (6.40) 23 −10.7 (6.05) 0.08
High—5.0 mg/kg 4.53 (2.24) 13 3.11 (0.44) <0.0001 41.18 (18.97) 15 −12.8 (6.59) 0.05
For each exposure group, Mean ± SD of percent methylation at each gene is shown along with a p-value from ANOVA comparing the groups. * Indicates Welch’s test was used instead of ANOVA because
variances were unequal (Leven’s test p = 0.04). Mixed-effects regression was also performed, and effect estimates are shown for the exposure group. For Tp53, the outcome consists of repeat measures of DNA
methylation at 9 CpG sites, and the model adjusts for offspring sex and CpG site. For H19, the outcome is repeat measures at 6 CpG sites, and the model adjusts for sex, site, and a random intercept for dam.
Int. J. Environ. Res. Public Health 2021, 18, 589 9 of 15
In blood, Tp53 methylation was higher in exposed versus control rats at both 3 weeks
and 3 months, yet this was only statistically significant at 3 months of age (ANOVA p = 0.07
for 3 weeks and p < 0.001 for 3 months). In repeated measures regression, this difference
was statistically significant in both exposure groups and at both time points (see Table 4).
There was some evidence for reduced blood DNA methylation at H19, though this was
only statistically significant at 3 months of age (ANOVA p = 0.04) with effect estimates
in the adjusted regression model of −10.7 ± 6.05%, p = 0.08 for low and −12.8 ± 6.59%,
p = 0.05 for high exposure groups compared to controls.
4. Discussion
In a rat study of perinatal exposure to two doses of AFB1, we observed effects on the
offspring with both doses at weaning (3 weeks of age) and also into adulthood (3 months)
after exposure had ceased. Perinatal AFB1 exposure was associated with decreased weight
(at birth, 3 weeks, and 3 months), altered lipids (decreased cholesterol at 3 weeks and
3 months, increased triglycerides at 3 weeks), and altered hormones (decreased testosterone,
progesterone, and LH) at p < 0.05. Both doses of perinatal AFB1 exposure were associated
with decreased methylation at the Tp53 promoter and increased methylation at the H19 ICR
in 3-week liver samples. In blood samples, associations (p < 0.05) were observed between
exposure and increased Tp53 methylation (3-weeks and 3-months) and decreased H19
methylation (3-months).
Our results showed that prenatal exposure to AFB1 decreased the weight of the animals
at birth and weight gain until 3 months of age. These results indicate that prenatal AFB1
exposure can decrease birth weight and affect the weight gain of the animals, even after ces-
sation of the exposure. The results of this study are in agreement with other studies [57–59].
Supriya et al. found a dose-dependent decrease in birth weight of rats prenatally exposed
to AFB1 during gestational days 12–19 of pregnancy [58,59]. A human study conducted
in The Gambia found inverse linear associations between maternal AFB1 concentrations
and weight and height of the offspring in the first year of life [60]. Some studies have also
shown that low birth weight may increase the risk of liver diseases and HCC in adulthood.
For example, a large cohort study of Danish children born between 1936–1980 [7] reported a
positive association between the risk estimates of low birth weight and primary liver cancer
and HCC in men. In women, the risk was associated with both low and high birth weight.
Similar results were also observed in a Finnish birth cohort; Sandboge et al. [8] concluded
that small birth size increased the odds of adult non-alcoholic fatty liver disease.
To the best of our knowledge, this is the first study to examine the effects of prenatal
AFB1 exposure on cholesterol and triglyceride concentrations in rats at weaning (3 weeks)
and after cessation of exposure in adulthood (3 months). Our results showed that prenatal
AFB1 exposure increased triglyceride concentrations at 3 weeks (low and high exposure
groups) and at 3 months (high exposure group). Interestingly, the high triglyceride concen-
trations observed were not correlated with body weight. Even so, the hypertriglyceridemia
observed may have other implications for conditions including coronary heart disease,
insulin resistance, or metabolic syndrome [61–63]. On the other hand, prenatal AFB1
exposure to both doses decreased cholesterol levels at 3 weeks and 3 months. These re-
sults differ from the response of cholesterol to AFB1 exposure in adulthood. Results from
our laboratory and others show that AFB1 exposure in adult rats increases cholesterol
levels [43,44,64,65]. This indicates that the mechanism of AFB1 toxicity in utero may differ
from that of adulthood and therefore requires further investigation.
Cholesterol is important for the biosynthesis of steroid hormones [48,66]. In this
study, prenatal AFB1 exposure significantly decreased concentrations of testosterone and
progesterone in male and female rats, respectively, and this could have resulted from
reduced cholesterol levels. Apart from the reduced cholesterol levels, the response of
steroid hormones to prenatal AFB1 exposure in this study was sex-dependent, which may
result from the influence of AFB1 on sex and developmental-stage specific differences in
the synthesis of these hormones [67]. Additionally, sex differences have been observed
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in the expression of genes involved in steroid hormone metabolism and response [68].
The decrease in testosterone observed in our study agrees with other studies [46,59]. The
study by Supriya and Reddy showed that prenatal AFB1 exposure resulted in decreased
circulating testosterone levels in male rats [59]. This decrease could have resulted from
reduced androgen biosynthesis as shown in their study by the reduction in the activities
of 3ß-hydroxysteroid dehydrogenase and 17ß-hydroxysteroid dehydrogenase in rat testis.
The reduction in testosterone may also be due to the ability of AFB1 to bind to Steroidogenic
acute regulatory (StAR) protein which aids the transport of cholesterol from the outer to
the inner mitochondrial membrane where it is converted to pregnenolone for testosterone
synthesis [46]. The decreased levels of progesterone observed in female rats may be
linked to the decreased level of LH since biosynthesis of steroid hormones is controlled by
gonadotropic hormones such as LH and FSH. Specifically, LH and FSH are involved in the
synthesis and regulation of steroid hormones: testosterone, progesterone, and estradiol [66].
In our study, LH levels were decreased in female rats, while FSH was not significantly
different in male or female rats. Our results are different from that of Supriya and Reddy,
where prenatal AFB1 exposure significantly increased LH and FSH. The differences between
studies could be related to exposure timing (acute vs. chronic). While our exposure spanned
from two weeks before mating, throughout pregnancy until weaning, theirs was limited
to gestational days 12–19. AFB1 has also been shown to decrease LH in adult rats [69,70]
and lactating buffalos [71]. Apart from the steroid and gonadotropic hormones, prenatal
AFB1 exposure also decreased prolactin at the low exposure dose and thyroxine at the high
exposure dose. Overall, the altered hormonal status of the exposed rats indicates that AFB1
could be an endocrine disruptor. Like other endocrine disruptors, its exposure in utero
may increase the risk for non-communicable diseases later-in-life [72].
The results of this and other studies suggest that AFB1 is not only a genotoxic agent
but also an epigenetic modifier. Widespread epigenetic aberrations including global hy-
pomethylation and hypermethylation of tumor suppressor genes are one of the hallmarks
of cancer [73], and some researchers even posit that epigenetic change contributes to all
hallmarks of cancer [74]. Most studies to date on AFB1 and the epigenome have used
clinical tumor samples or in vitro models (i.e., human hepatocytes). The in vitro studies
observed changes to DNA methylation, miRNA expression, and gene expression following
AFB1 exposure in human primary hepatocytes or hepatic stem cells (HepaRG) [33,75–77].
In tumor samples from HCC patients, DNA methylation levels at repetitive elements and
genes including GSTP1, RASSF1A, and p16 have been correlated with biomarkers of AFB1
exposure [20,21,78,79]. There is growing evidence that gestational exposures can alter
epigenetic programming and thereby increase the risk for the development of cancers later
in life. Most of the evidence to date centers around endocrine-disrupting chemicals and
the development of reproductive tract, breast, and prostate cancers [3].
To our knowledge, ours is the first study to assess whether early life AFB1 exposure
modifies the epigenome into adulthood, potentially contributing to risk for HCC or other
cancers. We observed differences by low and high AFB1 exposure in liver and blood at the
tumor suppressor gene, Tp53, and at the imprinted gene, H19. One epidemiological study
of mother-infant pairs from The Gambia reported associations between early gestation
AFB1 and DNA methylation of infant samples using an epigenome-wide approach at
71 CpG sites including genes involved in growth and immune function [19]. In this
study, we selected two genes for analysis that are relevant to carcinogenesis and have
evidence for environmental liability by early-life exposures. Tp53 is a well-characterized
tumor suppressor gene, and mutations in this gene have been linked to HCC along with
other cancers [80,81]. The promoter region of Tp53 assessed in this study was previously
shown to be responsive to a gestational diet of malnutrition. In offspring with gestational
exposure to reduced protein, Tp53 methylation was reduced, and protein expression
increased in the kidney at 2 and 3 months of age. Interestingly, this was reversed when
folic acid supplementation was given after weaning [55], highlighting the dynamic nature
of epigenetics and the possibility for interventions to improve health trajectories. H19 is an
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imprinted gene important to regulating fetal growth; DNA methylation at the regulatory
ICRs of this gene is modifiable by prenatal exposures to environmental chemicals and
diet [82–85]. In healthy tissue, H19 expression is downregulated after birth, but it reappears
in many tumors. H19 is now widely believed to be an oncogene that contributes to tumor
initiation and progression for many cancers [50,51] including HCC [86]. This study provides
evidence for perinatal AFB1 exposure and altered liver and blood DNA methylation of
H19 in rats. Whether this early life epigenetic programming influences downstream cancer
risk in rats, and more importantly in humans, is yet unknown.
In this study, aflatoxin exposure led to decreased Tp53 methylation in the liver, yet
increased in the blood. Likewise, the direction of effect on H19 methylation from AFB1
exposure was opposite for liver and blood. In human studies, when target tissues are
not accessible, blood DNA methylation is often used to approximate effects in tissues of
interest. In this study, both tissues did have significant DNA methylation changes by
exposure. However, given the difference in the direction of effect, using blood to predict
effects in the liver is not appropriate for every gene. Results in blood-only studies need to
be interpreted with caution.
This study had several advantages, including the modeling of a longer-term and
daily chronic AFB1 exposure from pre-conception through lactation and follow-up of the
offspring into adulthood. In addition to weight, we assessed hormone levels, lipids, and
epigenetics in two tissues. The use of blood (a surrogate tissue) in addition to the target
tissue (liver) of interest is relevant because human epigenetic studies are typically restricted
to the use of easily accessible surrogate tissues such as saliva or blood. This study had
limitations, including a small sample size within each exposure group and the inability
to perform epigenetic analysis on the 3-month liver samples. Functional validation was
not performed to assess whether epigenetic changes led to changes in gene or protein
expression. We only assessed two genes, selected by a hypothesis-driven approach; many
more genes could be dysregulated by AFB1 exposure that are relevant to developmental
processes and cancer risk. While the 3-month follow-up was a strength, we did not follow
rodents into mid- or late-adulthood and assess the incidence of cancer.
5. Conclusions
In this study of daily AFB1 exposure from pre-conception through lactation, we
report statistically significant effects in the offspring at 3 weeks and 3 months of age.
Results from this study showed that prenatal exposure to AFB1 reduced body weight
and disrupted lipid and hormone levels even after cessation of exposure. These changes
could have implications for increasing the risk of diseases later in life. The mechanisms
associated with these changes require further exploration. DNA methylation at two genes
important for cancer risk and development was different in exposed rodents’ liver and
blood samples. The direction of association between exposure and DNA methylation
was opposite in liver and blood for both H19 and Tp53, cautioning the interpretation of
epidemiological studies that only have access to blood. Future research in rodent models of
AFB1 exposure or human populations should perform epigenome-wide analysis coupled
with transcriptomics and ideally a long-term follow-up to identify reprogrammed genes
that contribute to HCC and other cancers. This knowledge will be critical to informing
policymaking and risk assessment of the impacts of AFB1 through food contamination in
vulnerable pregnant women and children.
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